|
1
|
Turati F, Carioli G, Bravi F, Ferraroni M,
Serraino D, Montella M, Giacosa A, Toffolutti F, Negri E, Levi F,
et al: Mediterranean diet and breast cancer risk. Nutrients.
10:E3262018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang F, Zhao N and Wu N: TNFR2 promotes
adriamycin resistance in breast cancer cells by repairing DNA
damage. Mol Med Rep. 16:2962–2968. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gregory RI and Shiekhattar R: MicroRNA
biogenesis and cancer. Cancer Res. 65:3509–3512. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fang L, Li H, Wang L, Hu J, Jin T, Wang J
and Yang BB: MicroRNA-17-5p promotes chemotherapeutic drug
resistance and tumour metastasis of colorectal cancer by repressing
PTEN expression. Oncotarget. 10:2974–2987. 2014.
|
|
5
|
Danesh H, Hashemi M, Bizhani F, Hashemi SM
and Bahari G: Association study of miR-100, miR-124-1, miR-218-2,
miR-301b, miR-605, and miR-4293 polymorphisms and the risk of
breast cancer in a sample of Iranian population. Gene. 647:73–78.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang GC, He QY, Tong DK, Wang CF, Liu K,
Ding C, Ji F and Zhang H: MiR-367 negatively regulates apoptosis
induced by adriamycin in osteosarcoma cells by targeting KLF4. J
Bone Oncol. 5:51–56. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chu S, Liu G, Xia P, Chen G, Shi F, Yi T
and Zhou H: miR-93 and PTEN: Key regulators of
doxorubicin-resistance and EMT in breast cancer. Oncol Rep.
38:2401–2407. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li BH, Yuan L, Shi RR and Wang JG:
Reversal of adriamycin resistance by digoxin in human breast cancer
cell line MCF-7/adriamycin and its mechanism. Sheng Li Xue Bao.
67:611–617. 2015.(In Chinese). PubMed/NCBI
|
|
9
|
Cao B, Li M, Zha W, Zhao Q, Gu R, Liu L,
Shi J, Zhou J, Zhou F, Wu X, et al: Metabolomic approach to
evaluating adriamycin pharmacodynamics and resistance in breast
cancer cells. Metabolomics. 9:960–973. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li N, Miao Y, Shan Y, Liu B, Li Y, Zhao L
and Jia L: MiR-106b and miR-93 regulate cell progression by
suppression of PTEN via PI3K/Akt pathway in breast cancer. Cell
Death Dis. 8:e27962017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang W, Bai J, Liu D, Wang S, Zhao N, Che
R and Zhang H: MiR-93-5p up-regulation is involved in non-small
cell lung cancer cells proliferation and migration and poor
prognosis. Gene. 647:13–20. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ma DH, Li BS, Liu JJ, Xiao YF, Yong X,
Wang SM, Wu YY, Zhu HB, Wang DX and Yang SM: miR-93-5p/IFNAR1 axis
promotes gastric cancer metastasis through activating the STAT3
signaling pathway. Cancer Lett. 408:23–32. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ansari MH, Irani S, Edalat H, Amin R and
Roushandeh Mohammadi A: Deregulation of miR-93 and miR-143 in human
esophageal cancer. Tumour Biol. 37:3097–3103. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu XF, Zou J, Bao ZJ and Dong J: miR-93
suppresses proliferation and colony formation of human colon cancer
stem cells. World J Gastroenterol. 17:4711–4717. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xiang Y, Liao XH, Yu CX, Yao A, Qin H, Li
JP, Hu P, Li H, Guo W, Gu CJ, et al: MiR-93-5p inhibits the EMT of
breast cancer cells via targeting MKL-1 and STAT3. Exp Cell Res.
357:135–144. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shyamasundar S, Lim JP and Bay BH: miR-93
inhibits the invasive potential of triple-negative breast cancer
cells in vitro via protein kinase WNK1. Int J Oncol.
49:2629–2636. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Deng ZQ, Qian J, Liu FQ, Lin J, Shao R,
Yin JY, Tang Q, Zhang M and He L: Expression level of miR-93 in
formalin-fixed paraffin-embedded tissues of breast cancer patients.
Genet Test Mol Biomarkers. 18:366–370. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kawami M, Yamada Y, Issarachot O,
Junyaprasert VB, Yumoto R and Takano M: P-gp modulating effect of
Azadirachta indica extract in multidrug-resistant cancer
cell lines. Pharmazie. 73:104–109. 2018.PubMed/NCBI
|
|
19
|
McCollum AK, Casagrande G and Kohn EC:
Caught in the middle: The role of Bag3 in disease. Biochem J.
425:e1–3. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang HQ, Liu BQ, Gao YY, Meng X, Guan Y,
Zhang HY and Du ZX: Inhibition of the JNK signalling pathway
enhances proteasome inhibitor-induced apoptosis of kidney cancer
cells by suppression of BAG3 expression. Br J Pharmacol.
158:1405–1412. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chiappetta G, Ammirante M, Basile A,
Rosati A, Festa M, Monaco M, Vuttariello E, Pasquinelli R, Arra C,
Zerilli M, et al: The antiapoptotic protein BAG3 is expressed in
thyroid carcinomas and modulates apoptosis mediated by tumor
necrosis factor-related apoptosis-inducing ligand. J Clin
Endocrinol Metab. 92:1159–1163. 2007. View Article : Google Scholar : PubMed/NCBI
|
